Fagron is active in 35+ countries in EMEA, North America, and Latin America. Fagron has sterile and non-sterile compounding facilities in Europe (the Netherlands, Belgium, and the Czech Republic), Israel, the United States, Colombia, and South Africa, which supply medications to pharmacies, hospitals, and clinics, as well as directly to patients in South Africa and Colombia.
Integrated Expertise
Fagron occupies a structurally unique position in the pharmaceutical compounding market: it is the only company operating globally, at scale, across the full value chain. This breadth of presence, spanning compounding services, branded product development, API sourcing, and regulatory compliance, creates competitive advantages that are difficult to replicate.
Scalability and Sourcing
Fagron’s diversified global footprint supports strong sourcing capabilities, high levels of product availability, and a broader assortment for customers. This scale enables cost efficiencies that smaller, regional players cannot access, while the Group’s agility allows it to adapt to local regulatory environments and market demands.
Asset-Light Model with Strong Cash Conversion
The Group’s asset-light operating model delivers attractive economics. Capital expenditure requirements are low, approximately 3.5% of revenues, enabling the business to convert a high proportion of EBITDA into cash. This financial profile provides meaningful flexibility to reinvest in organic growth, fund acquisitions, and maintain a disciplined balance sheet.
Three Integrated Segments
- Essentials: Raw materials, equipment, packaging and supplies for pharmaceutical compounding, enabling pharmacists and healthcare providers to deliver safe and effective treatments.
- Brands: Proprietary, science-based formulations that build pricing power and clinical differentiation.
- Compounding Services: Core operations providing customized medications across therapy areas and geographies.
Mergers and Acquisitions
Understand Our Acquisition Strategy
